Have you heard of 2FDCK or 2-Fluorodeschloroketamine in your area? If you have any information regarding this substance, please fill out the form below.

This week's NDEWS Hotspot Alerts report includes 32 counties with higher-than-expected drug-related 911 dispatch counts over the previous 7-day period. Read more here. Click here to read more about NDEWS Hotspot Alerts

A study recently published in Drug and Alcohol Dependence Reports, led by NDEWS Deputy Director Dr. Joseph Palamar, compared trends in self-reported drug use, drug positivity, and adjusted prevalence from 2016 to 2022 among nightclub and festival attendees in New York City who use ecstasy. Results showed decreases in the detection of MDMA, synthetic cathinones, and MDA. The authors hypothesized that adulteration of ecstasy in the US has been decreasing. Read the study here.

NDEWS recently partnered with the Center for Forensic Science Research & Education (CFSRE)’s NPS Discovery to assist in investigations of exposures involving novel or unknown substances. Requests for assistance can be submitted to NDEWS, and NPS Discovery will facilitate the comprehensive testing of the drug and/or drug paraphernalia for the identification of drugs and adulterants, including a wide array of novel psychoactive substances (NPS). This is a phenomenal opportunity. It can be completed with strict anonymity. While the form asks for identifiers, when you submit the material, it will be anonymous. Complete the query form here.

A study recently published in Drug Testing and Analysis investigated the cannabinoid activation potential of the newly emerging generic ban-evading brominated synthetic cannabinoid receptor agonists (SCRAs). The authors found that given their pronounced activation potential, it is expected that this class of SCRAs will expand in the future, and that constant monitoring of the market and of the pharmacological properties of these substances is essential. Read the study here.

In a letter addressed to the public last Friday, Drug Enforcement Administration (DEA) Administrator Anne Milgram outlined steps the DEA is taking to increase prescription stimulant production. The DEA has been in communication with relevant manufacturers, and 17 of the 18 have agreed to increase their production of stimulant medications. The letter also noted that manufacturers did not meet their allotted production quotas in 2022, leading to a shortfall of 1 billion doses not made, with 2023 indicating a similar trend. Read the letter here.

Share your research, news, and events through our submission form

Share your comments on our newsletter through our feedback form

Follow NDEWS on Twitter: @NDEWSnews